ProQR Therapeutics (PRQR) Retained Earnings (2015 - 2025)
ProQR Therapeutics recorded quarterly Retained Earnings of $33.4 million in Q4 2025, up 107.32% quarter-over-quarter from -$456.5 million in Q4 2024, and up 107.32% year-over-year from $16.1 million in Q4 2024.
ProQR Therapeutics' Retained Earnings history runs 11 years deep, the most recent figure standing at $33.4 million for Q4 2025.
- In Q4 2025, Retained Earnings rose 107.32% year-over-year to $33.4 million; the TTM figure through Dec 2025 stood at $33.4 million (up 107.32% YoY), while the FY2025 annual figure was $33.4 million, up 107.32% from the prior year.
- Retained Earnings came in at $33.4 million for Q4 2025 at ProQR Therapeutics, up from -$456.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $33.4 million in Q4 2025 to a low of -$456.5 million in Q4 2024.
- A 5-year average of -$237.4 million and a median of -$363.5 million in 2021 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings surged 108.49% in 2022 and tumbled 1496.81% in 2023, its largest moves.
- ProQR Therapeutics' Retained Earnings stood at -$363.5 million in 2021, then jumped by 108.49% to $30.9 million in 2022, then sank by 1496.81% to -$431.3 million in 2023, then slipped by 5.84% to -$456.5 million in 2024, then soared by 107.32% to $33.4 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $33.4 million, -$456.5 million, and -$431.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | 33.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 33.40 Mn |
| Dec 31, 2024 | -456.46 Mn |
| Dec 31, 2023 | -431.29 Mn |
| Dec 31, 2022 | 30.88 Mn |
| Dec 31, 2021 | -363.52 Mn |
| Dec 31, 2020 | -307.31 Mn |
| Sep 30, 2020 | -297,859.70 |
| Jun 30, 2020 | -148,697.12 |
| Mar 31, 2020 | 282,608.39 |
| Dec 31, 2019 | -234.38 Mn |
| Sep 30, 2019 | 163,571.31 |
| Jun 30, 2019 | -42,698.29 |
| Mar 31, 2019 | 13,639.55 |
| Dec 31, 2018 | -177.42 Mn |
| Sep 30, 2018 | -17,446.94 |
| Jun 30, 2018 | 17,901.67 |
| Mar 31, 2018 | -31,941.85 |
| Dec 31, 2017 | -140.55 Mn |
| Sep 30, 2017 | 133,957.21 |
| Jun 30, 2017 | 71,470.71 |
| Mar 31, 2017 | 2,130.81 |
| Dec 31, 2016 | -81.77 Mn |
| Jun 30, 2016 | -5,649.38 |
| Mar 31, 2016 | 5,515.06 |
| Dec 31, 2015 | 1,096.12 |